MedTrace Logo

A Retrospective Review of DEXTENZA 0.4 mg inseRt Following Corneal Transplant or Cataract Surgery

NCT04975971 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 25

Last updated 2021-07-26

No results posted yet for this study

Summary

A Retrospective Review of Pain and Inflammation Resolution Outcomes in Patients Who Received DEXTENZA Intracanalicular Dexamethasone (0.4 mg) Insert Prior to or Following Corneal transplant or Cataract surgery

Conditions

  • Anterior Chamber Inflammation
  • Ocular Pain
  • Corneal Edema
  • Corneal Defect
  • Penetrating KeratoPlasty
  • Nuclear Cataract
  • Cortical Cataract
  • Cataract Senile

Interventions

DRUG

Dextenza 0.4Mg Ophthalmic Insert

DEXTENZA is a corticosteroid intracanalicular insert placed in the punctum, a natural opening in the eye lid, and into the canaliculus and is designed to deliver dexamethasone to the ocular surface for up to 30 days without preservatives.

Sponsors & Collaborators

  • Nicole Fram M.D.

    lead OTHER

Principal Investigators

  • Nicole R Fram, M.D. · Advanced Vision Care

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-09
Primary Completion
2021-05-19
Completion
2021-05-19
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04975971 on ClinicalTrials.gov